Impact of Leukoaraiosis Severity on the Association of Time to Successful Reperfusion with 90-Day Functional Outcome After Large Vessel Occlusion Stroke.


Journal

Translational stroke research
ISSN: 1868-601X
Titre abrégé: Transl Stroke Res
Pays: United States
ID NLM: 101517297

Informations de publication

Date de publication:
02 2020
Historique:
received: 05 10 2018
accepted: 27 03 2019
revised: 22 01 2019
pubmed: 14 4 2019
medline: 27 7 2021
entrez: 14 4 2019
Statut: ppublish

Résumé

The chance for a favorable outcome after mechanical thrombectomy (MT) for large vessel occlusion stroke decreases with the symptom onset-to-reperfusion time (OTR). Patients with severe leukoaraiosis are at increased risk for a poor outcome after MT. However, whether leukoaraiosis modulates to the association between OTR and 90-day functional outcome is uncertain. We retrospectively analyzed 144 consecutive patients with successful (TICI ≥ 2b/3) MT for anterior circulation large vessel occlusion within 24 h form OTR between January 2012 to November 2016. Leukoaraiosis was dichotomized to absent-to-mild (van Swieten scale score 0-2) versus moderate-to-severe (3-4) as assessed on admission head CT. Multiple linear, logistic, and ordinal regression analyses were used to determine the association between leukoaraiosis, OTR, and 90-day modified Rankin Scale (mRS) score, after adjustment for pertinent covariates. Leukoaraiosis was independently associated with the OTR on multivariable linear regression (p = 0.003). The association between OTR and 90-day outcome depended on the degree of pre-existing leukoaraiosis burden as shown by a significant leukoaraiosis-by-OTR interaction on multivariable logistic regression (OR 0.76, 95% CI 0.58-0.98, p = 0.037) and multivariable ordinal regression (OR 0.87, 95% CI 0.78-0.97, p = 0.011). Pre-existing leukoaraiosis is associated with the 90-day functional outcome after successful reperfusion and impacts the association between the OTR and 90-day mRS among patients undergoing MT. Patients with high leukoaraiosis burden need to present earlier than patients with low leukoaraiosis burden for a similar favorable outcome. Pending confirmation, these results may have important implications for optimizing patient selection for acute stroke therapies.

Identifiants

pubmed: 30980282
doi: 10.1007/s12975-019-00703-0
pii: 10.1007/s12975-019-00703-0
pmc: PMC6925352
mid: NIHMS1063046
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

39-49

Subventions

Organisme : NINDS NIH HHS
ID : K08 NS091499
Pays : United States
Organisme : NINDS NIH HHS
ID : K08NS091499
Pays : United States

Références

Stroke. 2011 Aug;42(8):2276-9
pubmed: 21680905
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
JAMA. 2016 Sep 27;316(12):1279-88
pubmed: 27673305
N Engl J Med. 2015 Jan 1;372(1):11-20
pubmed: 25517348
N Engl J Med. 2015 Mar 12;372(11):1019-30
pubmed: 25671798
N Engl J Med. 2015 Mar 12;372(11):1009-18
pubmed: 25671797
Lancet. 2000 May 13;355(9216):1670-4
pubmed: 10905241
Cerebrovasc Dis. 2012;33(6):525-31
pubmed: 22538962
Neurology. 2017 May 30;88(22):2123-2127
pubmed: 28455382
Lancet Neurol. 2016 Oct;15(11):1138-47
pubmed: 27567239
Stroke. 2018 Mar;49(3):e46-e110
pubmed: 29367334
Neurology. 2017 Feb 14;88(7):638-645
pubmed: 28130468
Stroke. 2014 Jul;45(7):2036-40
pubmed: 24876081
Stroke. 2013 May;44(5):e43
pubmed: 23463756
Stroke. 2017 Sep;48(9):2621-2627
pubmed: 28794271
Stroke. 2008 May;39(5):1409-13
pubmed: 18340093
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
J Stroke. 2017 May;19(2):121-130
pubmed: 28592779
N Engl J Med. 2015 Jun 11;372(24):2285-95
pubmed: 25882376
Stroke. 2014 Feb;45(2):479-85
pubmed: 24370756
World Neurosurg. 2018 Dec;120:e976-e983
pubmed: 30196176
Stroke. 2012 Jul;43(7):1806-11
pubmed: 22581819
Stroke. 2017 Oct;48(10):2892-2894
pubmed: 28887393
Stroke. 2003 Aug;34(8):e109-37
pubmed: 12869717
Neuroepidemiology. 2013;40(1):13-22
pubmed: 23075702
Stroke. 2006 Mar;37(3):836-40
pubmed: 16439704
J Neurointerv Surg. 2019 Feb;11(2):137-140
pubmed: 30045947
Stroke. 2018 Feb;49(2):498-500
pubmed: 29242390
Neurology. 2006 Jan 10;66(1):23-9
pubmed: 16401840
Int J Stroke. 2017 Oct;12(8):896-905
pubmed: 28946832
Int J Stroke. 2019 Jan;14(1):23-31
pubmed: 30188259
J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1080-3
pubmed: 2292703
Stroke. 2016 Oct;47(10):2526-33
pubmed: 27633020
Stroke. 2015 Oct;46(10):3020-35
pubmed: 26123479
AJNR Am J Neuroradiol. 2014 Nov-Dec;35(11):2070-5
pubmed: 24994827
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
Stroke. 2014 Mar;45(3):689-95
pubmed: 24523039
Stroke. 2013 Jan;44(1):61-7
pubmed: 23233384
Front Neurol. 2017 Mar 14;8:98
pubmed: 28352248
J Neurol. 2017 Mar;264(3):448-452
pubmed: 28004198
N Engl J Med. 2015 Jun 11;372(24):2296-306
pubmed: 25882510
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
J Neurointerv Surg. 2019 Jul;11(7):670-674
pubmed: 30530773
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Int J Stroke. 2017 Aug;12(6):641-652
pubmed: 28569123
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852

Auteurs

Abdul Ghani Mikati (AG)

Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave, North Worcester, MA, 01655, USA.

Max Mandelbaum (M)

Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave, North Worcester, MA, 01655, USA.

Shweta Sapnar (S)

Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave, North Worcester, MA, 01655, USA.

Ajit S Puri (AS)

Department of Radiology, University of Massachusetts Medical School, Worcester, MA, USA.
Department of Neurosurgery, University of Massachusetts Medical School, Worcester, MA, USA.

Brian Silver (B)

Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave, North Worcester, MA, 01655, USA.

Richard P Goddeau (RP)

Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave, North Worcester, MA, 01655, USA.

Diogo C Haussen (DC)

Department of Neurology, Emory University/Marcus Stroke and Neuroscience Center-Grady Memorial Hospital, Atlanta, GA, USA.

Majaz Moonis (M)

Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave, North Worcester, MA, 01655, USA.

Adalia H Jun-O'Connell (AH)

Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave, North Worcester, MA, 01655, USA.

Nils Henninger (N)

Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave, North Worcester, MA, 01655, USA. nils.henninger@umassmed.edu.
Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA. nils.henninger@umassmed.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH